MSLE News

Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study

Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience

Satellos to Participate in Upcoming Investor Conferences

Satellos Granted Composition of Matter Patent for Forazapadin

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Satellos to Present at the 31st Annual Congress of the World Muscle Society

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Satellos to Participate in Upcoming Investor Conferences

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress